Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27089683 | 1.00 | MDM2 (0.41) | MDM2 | |
| SCHEMBL23366007 | 1.00 | MDM2 (0.41) | MDM2 | |
| SCHEMBL21501958 | 1.00 | MDM2 (0.41) | MDM2 | |
| SCHEMBL17827399 | 0.91 | MDM2 (0.37) | MDM2 | |
| SCHEMBL14519184 | 0.91 | MDM2 (0.37) | MDM2 | |
| SCHEMBL14519175 | 0.91 | MDM2 (0.37) | MDM2 | |
| SCHEMBL12384536 | 0.85 | MDM2 (0.35) | MDM2 | |
| SCHEMBL10198508 | 0.85 | MDM2 (0.35) | MDM2 | |
| SCHEMBL409484 | 0.85 | MDM2 (0.35) | MDM2 | |
| SCHEMBL17827400 | 0.82 | MDM2 (0.32) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | MDM2 3147/4885 |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | MDM2 1103/4885 |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | BTK, SYK, LYN | MDM2 2026/4885 |
| US-10012650-B2 | Assays for BTK inhibitors | BTK, SYK, LYN | MDM2 2026/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | MDM2 1103/4885 |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | MDM2 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.